secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2023-05-01T23:59:59+00:00
Accession:  0001193125-23-128616
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics reports positive Phase 2a data for bexotegrast in IPF; FVC decline reduced 68% vs placebo
--------------------------------------------------------------------------------

- Bexotegrast 320 mg well tolerated up to 40 weeks; no drug-related serious adverse events.
- FVC decline reduced 68% vs placebo: mean FVCpp change -0.8% vs -2.5% at Week 24.
- 89% of patients with FVC increase at Week 12 maintained increase through Week 24.
- QLF imaging showed fibrosis stabilization in bexotegrast group vs progression in placebo.
- BEACON-IPF Phase 2b trial (160/320 mg, ~270 patients) to initiate in mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000119312523128616/0001193125-23-128616-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000119312523128616/d440511d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-128616

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer